
On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE (NASDAQ:BNTX).
The data were presented in an oral session at the 2024 European Society of Medical Oncology Asia Annual Meeting in Singapore and showed encouraging antitumor activity alongside a manageable safety profile in heavily pretreated patients with locally advanced or metastatic solid tumors.